Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor-Reference-Cited by-同舟云学术

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor

Published:2011-03-31 Issue:20 Volume:117 Page:4633-4641
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sawaki Akira,Nishida Toshirou,Doi Toshihiko,Yamada Yasuhide,Komatsu Yoshito,Kanda Tatsuo,Kakeji Yoshihiro,Onozawa Yusuke,Yamasaki Makoto,Ohtsu Atsushi

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26120/fullpdf

Reference29 articles.

1. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

2. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor;Heinrich;J Clin Oncol,2003

3. PDGFRA activating mutations in gastrointestinal stromal tumors;Heinrich;Science,2003

4. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group;Blay;J Clin Oncol,2007

5. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia;Cancers;2023-08-20

2. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours;Cancers;2023-08-13

3. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review;Frontiers in Pharmacology;2023-05-23

4. Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors;International Journal of Molecular Sciences;2023-03-23

5. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022;Journal of the National Comprehensive Cancer Network;2022-11